Low-density lipoprotein (LDL) oxidation is a key step in atherogenesis, promoting the formation of lipid-laden macrophages. Here, we compared the effects of copper-oxidized LDLs (OxLDLs) and of the more physiologically relevant myeloperoxidase-oxidized LDLs (MoxLDLs) in murine RAW264.7 macrophages and in human peripheral blood monocyte-derived macrophages. Both oxidized LDLs, contrary to native LDLs, induced foam cell formation and an intracellular accumulation of reactive oxygen species (ROS). This oxidative stress was responsible for the activation of the NF-E2-related factor 2 (Nrf2) transcription factor, and the subsequent Nrf2-dependent overexpression of the antioxidant genes, Gclm and HO-1, as evidenced by the invalidation of Nrf2 by RNAi. MoxLDLs always induced a stronger response than OxLDLs. These differences could be partly explained by specific ROS-producing mechanisms differing between OxLDLs and MoxLDLs. Whereas both types of oxidized LDLs caused ROS production partly by NADPH oxidase, only MoxLDLs-induced ROS production was dependent on cytosolic PLA2. This study highlights that OxLDLs and MoxLDLs induce an oxidative stress, through distinct ROS-producing mechanisms, which is responsible for the differential activation of the Nrf2 pathway. These data clearly suggest that results obtained until now with copper oxidized-LDLs should be carefully reevaluated, taking into consideration physiologically more relevant oxidized LDLs. Antioxid. Redox Signal. 13, 1491–1502.
CarrAC, MyzakMC, StockerR, McCallMR, FreiB. Myeloperoxidase binds to low-density lipoprotein: potential implications for atherosclerosis. FEBS Lett, 487:176–180. 2000.
6.
ChanK, KanYW. Nrf2 is essential for protection against acute pulmonary injury in mice. Proc Natl Acad Sci USA, 96:12731–12736. 1999.
7.
ChungHT, PaeHO, ChaYN. Role of heme oxygenase-1 in vascular disease. Curr Pharm Des, 14:422–428. 2008.
8.
DaughertyA, DunnJL, RateriDL, HeineckeJW. Myeloperoxidase, a catalyst for lipoprotein oxidation, is expressed in human atherosclerotic lesions. J Clin Invest, 94:437–444. 1994.
9.
DengTL, YuL, GeYK, ZhangL, ZhengXX. Intracellular-free calcium dynamics and F-actin alteration in the formation of macrophage foam cells. Biochem Biophys Res Commun, 338:748–756. 2005.
10.
DrogeW. Free radicals in the physiological control of cell function. Physiol Rev, 82:47–95. 2002.
11.
FrancoR, SchoneveldOJ, PappaA, PanayiotidisMI. The central role of glutathione in the pathophysiology of human diseases. Arch Physiol Biochem, 113:234–258. 2007.
12.
HazenSL, HeineckeJW. 3-Chlorotyrosine, a specific marker of myeloperoxidase-catalyzed oxidation, is markedly elevated in low density lipoprotein isolated from human atherosclerotic intima. J Clin Invest, 99:2075–2081. 1997.
IshiiT, ItohK, RuizE, LeakeDS, UnokiH, YamamotoM, MannGE. Role of Nrf2 in the regulation of CD36 and stress protein expression in murine macrophages: activation by oxidatively modified LDL and 4-hydroxynonenal. Circ Res, 94:609–616. 2004.
KenslerTW, WakabayashiN, BiswalS. Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway. Annu Rev Pharmacol Toxicol, 47:89–116. 2007.
KlinknerAM, WaitesCR, KernsWD, BugelskiPJ. Evidence of foam cell and cholesterol crystal formation in macrophages incubated with oxidized LDL by fluorescence and electron microscopy. J Histochem Cytochem, 43:1071–1078. 1995.
19.
LeeJM, JohnsonJA. An important role of Nrf2-ARE pathway in the cellular defense mechanism. J Biochem Mol Biol, 37:139–143. 2004.
20.
LeeuwenburghC, RasmussenJE, HsuFF, MuellerDM, PennathurS, HeineckeJW. Mass spectrometric quantification of markers for protein oxidation by tyrosyl radical, copper, and hydroxyl radical in low density lipoprotein isolated from human atherosclerotic plaques. J Biol Chem, 272:3520–3526. 1997.
21.
LupoG, NicotraA, GiurdanellaG, AnfusoCD, RomeoL, BiondiG, TiroloC, MarchettiB, RagusaN, AlberghinaM. Activation of phospholipase A(2) and MAP kinases by oxidized low-density lipoproteins in immortalized GP8.39 endothelial cells. Biochim Biophys Acta, 1735:135–150. 2005.
MainesMD. The heme oxygenase system: A regulator of second messenger gases. Annu Rev Pharmacol Toxicol, 37:517–554. 1997.
24.
MalleE, MarscheG, ArnholdJ, DaviesMJ. Modification of low-density lipoprotein by myeloperoxidase-derived oxidants and reagent hypochlorous acid. Biochim Biophys Acta, 1761:392–415. 2006.
25.
MarscheG, ZimmermannR, HoriuchiS, TandonNN, SattlerW, MalleE. Class B scavenger receptors CD36 and SR-BI are receptors for hypochlorite-modified low density lipoprotein. J Biol Chem, 278:47562–47570. 2003.
26.
MaziereC, MaziereJC. Activation of transcription factors and gene expression by oxidized low-density lipoprotein. Free Radic Biol Med, 2008.
27.
McMillenTS, HeineckeJW, LeBoeufRC. Expression of human myeloperoxidase by macrophages promotes atherosclerosis in mice. Circulation, 111:2798–2804. 2005.
28.
MoguilevskyN, Zouaoui BoudjeltiaK, BabarS, DelreeP, LegssyerI, CarpentierY, VanhaeverbeekM, DucobuJ. Monoclonal antibodies against LDL progressively oxidized by myeloperoxidase react with ApoB-100 protein moiety and human atherosclerotic lesions. Biochem Biophys Res Commun, 323:1223–1228. 2004.
MorseD, ChoiAM. Heme oxygenase-1: The "emerging molecule" has arrived. Am J Respir Cell Mol Biol, 27:8–16. 2002.
31.
MullerK, DulkuS, HardwickSJ, SkepperJN, MitchinsonMJ. Changes in vimentin in human macrophages during apoptosis induced by oxidised low density lipoprotein. Atherosclerosis, 156:133–144. 2001.
SharifO, BolshakovVN, RainesS, NewhamP, PerkinsND. Transcriptional profiling of the LPS induced NF-kappaB response in macrophages. BMC Immunol, 8:1. 2007.
34.
ShioseA, SumimotoH. Arachidonic acid and phosphorylation synergistically induce a conformational change of p47phox to activate the phagocyte NADPH oxidase. J Biol Chem, 275:13793–13801. 2000.
35.
SinghU, JialalI. Oxidative stress and atherosclerosis. Pathophysiology, 13:129–142. 2006.
36.
StockerR, KeaneyJFJr.Role of oxidative modifications in atherosclerosis. Physiol Rev, 84:1381–1478. 2004.
37.
ThomasCE. The influence of medium components on Cu(2+)-dependent oxidation of low-density lipoproteins and its sensitivity to superoxide dismutase. Biochim Biophys Acta, 1128:50–57. 1992.
38.
TownsendDM, TewKD, TapieroH. The importance of glutathione in human disease. Biomed Pharmacother, 57:145–155. 2003.
39.
VaesM, Zouaoui BoudjeltiaK, Van AntwerpenP, BabarS, DegerF, VanhaeverbeekM, DucobuJ. Low-density lipoprotein oxidation by myeloperoxidase occurs in the blood circulation during hemodialysis. Atherosclerosis Supplements, 7:525. 2006.
40.
ValkoM, LeibfritzD, MoncolJ, CroninMT, MazurM, TelserJ. Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol, 39:44–84. 2007.
41.
WittwerJ, HersbergerM. The two faces of the 15-lipoxygenase in atherosclerosis. Prostaglandins Leukot Essent Fatty Acids, 77:67–77. 2007.
42.
YagiK. A simple fluorometric assay for lipoperoxide in blood plasma. Biochem Med, 15:212–216. 1976.
43.
YamaguchiM, SatoH, BannaiS. Induction of stress proteins in mouse peritoneal macrophages by oxidized low-density lipoprotein. Biochem Biophys Res Commun, 193:1198–1201. 1993.
44.
YanLJ, LodgeJK, TraberMG, MatsugoS, PackerL. Comparison between copper-mediated and hypochlorite-mediated modifications of human low density lipoproteins evaluated by protein carbonyl formation. J Lipid Res, 38:992–1001. 1997.
45.
YokoyamaC, WangX, BriggsMR, AdmonA, WuJ, HuaX, GoldsteinJL, BrownMS. SREBP-1, a basic-helix-loop-helix-leucine zipper protein that controls transcription of the low density lipoprotein receptor gene. Cell, 75:187–197. 1993.
46.
ZarevS, Bonnefont–RousselotD, JedidiI, CossonC, CouturierM, LegrandA, BeaudeuxJL, TherondP. Extent of copper LDL oxidation depends on oxidation time and copper/LDL ratio: chemical characterization. Arch Biochem Biophys, 420:68–78. 2003.
47.
ZiouzenkovaO, SevanianA, AbujaPM, RamosP, EsterbauerH. Copper can promote oxidation of LDL by markedly different mechanisms. Free Radic Biol Med, 24:607–623. 1998.
48.
Zouaoui BoudjeltiaK, LegssyerI, Van AntwerpenP, KisokaRL, BabarS, MoguilevskyN, DelreeP, DucobuJ, RemacleC, VanhaeverbeekM, BroheeD. Triggering of inflammatory response by myeloperoxidase-oxidized LDL. Biochem Cell Biol, 84:805–812. 2006.
49.
Zouaoui BoudjeltiaK, TragasG, BabarS, MoscarielloA, NuyensV, Van AntwerpenP, GilbertO, DucobuJ, BroheeD, VanhaeverbeekM, Van MeerhaegheA. Effects of oxygen therapy on systemic inflammation and myeloperoxidase modified LDL in hypoxemic COPD patients. Atherosclerosis, 2009.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
